For US Healthcare Professionals Only
Congress Materials
FILTER
FILTER
“How quickly will I feel better with this new drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Achieving Stringent Disease Control Criteria was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
Association of Hidradenitis Suppurativa Flares and the Menstrual Cycle: A Prospective Cohort Study
Barriers and Facilitators to Quality HS Biologic Care and Outcomes for the Medicaid Population Across US States
Bimekizumab 2-year Efficacy by Prior Biologic Use in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 2-Year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Oral Presentation Symposium on Hidradenitis Suppurativa Advances (SHSA), 2024
Bimekizumab 2-year Impact on HS Symptoms by Baseline Draining Tunnel Count: Data from BE HEARD EXT
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Oral Presentation Symposium on Hidradenitis Suppurativa Advances (SHSA), 2024
Bimekizumab 2-Year Impact on HSSQ Skin Pain in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 2-year Maintenance of Response in Moderate to Severe HS: Data from BE HEARD EXT
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Poster Winter Clinical Miami, 2025
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Poster Maui Derm Hawaii, 2025
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Bimekizumab clinical efficacy in important body regions and health-related quality of life in patients with plaque psoriasis: Data from four phase 3/3b comparator-controlled trial periods
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bimekizumab effect on the need for concomitant rescue interventions by HiSCR level in patients with moderate to severe hidradenitis suppurativa from BE HEARD I&II
Bimekizumab Efficacy Across Subgroups of Patients With Moderate to Severe Plaque Psoriasis: Pooled Analysis From up to 3 Years of Treatment in 5 Phase 3/3b Clinical Trials
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
Bimekizumab efficacy and safety in patients with psoriatic arthritis and psoriasis: Up to 2-year results from two phase 3 studies
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
Poster Maui Derm Hawaii, 2025
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Poster Winter Clinical Miami, 2025
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Oral Presentation European Academy of Dermatology & Venerology (EADV), 2024
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Poster Maui Derm Hawaii, 2025
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Poster Winter Clinical Miami, 2025
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-term Results from a Phase 3 Study and Open-Label Extension
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Bimekizumab efficacy by body region in plaque psoriasis: Comparative analyses from four phase 3/3b studies
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Poster Fall Clinical PA + NP, 2024
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Bimekizumab efficacy from treatment initiation through 4 years in patients with plaque psoriasis: A comprehensive, long-term, pooled analysis from BE BRIGHT
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in fatigue observed in two phase 3 studies
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Bimekizumab impact on clinical markers of liver fibrosis and key liver parameters in patients with moderate to severe plaque psoriasis: Long-term pooled data from BE BRIGHT
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
Bimekizumab Impact on Draining Tunnels Over 2 Years in HS: Data from BE HEARD EXT
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on draining tunnels: A dynamic assessment in patients with moderate to severe HS using pooled Week 48 results from BE HEARD I&II
Poster Winter Clinical Miami, 2025
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Poster Maui Derm Hawaii, 2025
Bimekizumab impact on flare in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
Oral Presentation European Academy of Dermatology & Venerology (EADV), 2024
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: Pooled Week 48 results from BE HEARD I&II
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
Bimekizumab in routine clinical practice: Baseline characteristics and treatment history of patients with moderate to severe plaque psoriasis from the second interim analysis of ELEVATE
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Bimekizumab long-term efficacy in patients with moderate to severe plaque psoriasis after switching from adalimumab, ustekinumab, or secukinumab: Results from up to 4 years of total treatment from BE BRIGHT and BE RADIANT
Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Mean percentage improvement in clinical outcomes over 4 years
Bimekizumab Maintained Efficacy Responses in Patients With Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-αα Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
Bimekizumab Maintained Stringent Clinical Responses Over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Poster Winter Clinical Miami, 2025
Bimekizumab maintenance of response at every visit over 4 years in patients with psoriasis achieving clear skin at Week 16: Results from four phase 3 trials
Bimekizumab maintenance of response from the end of pivotal trials through 4 years: Results in patients with moderate to severe plaque psoriasis from BE BRIGHT
Bimekizumab PASI response levels in Week 16 PASI responders with moderate to severe plaque psoriasis through 4 years: Results from BE BRIGHT
Bimekizumab reduced psoriatic arthritis impact in patients with psoriasis: Up to 2-year results from two phase 3 studies
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Poster Fall Clinical PA + NP, 2024
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicenter, randomized, open-label studies
Bimekizumab safe and effective self-administration using 2 mL devices by patients with moderate to severe plaque psoriasis: Results from two multicentre, randomised, open-label studies
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Poster Fall Clinical PA + NP, 2024
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Poster Winter Clinical Miami, 2025
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Poster Maui Derm Hawaii, 2025
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab Safety in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Rates of Hepatic Events and Transaminase Elevations in Phase 3 Trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab simultaneous skin and nail clearance in patients with psoriasis: Assessing comparative efficacy in four phase 3/3b studies
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Bimekizumab treatment history and clinical outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Bimekizumab treatment history and quality of life outcomes in patients with moderate to severe plaque psoriasis in routine clinical practice: Results from the second interim analysis of ELEVATE
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Oral Presentation European Academy of Dermatology & Venerology (EADV), 2024
Bimekizumab treatment in plaque psoriasis resulted in a rapid and deep normalisation of molecular signatures associated with PASI sub-components, that preceded clinical skin clearance
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
Bimekizumab treatment in psoriasis patients: A mechanistic understanding of the durable clinical response
Oral Presentation American College of Rheumatology (ACR), 2024
Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Bimekizumab Treatment was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
Bimekizumab-Treated Patients With Psoriatic Arthritis Showed Sustained Improvements in HRQoL and Work Productivity Up To 2 Years
Bimekizumab: Exploring the fast onset, high level, and durability of clinical and molecular responses in patients with psoriatic disease – Design and rationale behind the exploratory, multicentre, open-label phase 3b BE UNIQUE study
Bimekizumab: Network meta-analysis to establish comparative efficacy in moderate-to-severe hidradenitis suppurativa patients
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Characteristics, Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States
Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-Hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study
Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: A post hoc analysis of the RAISE-XT study
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Concomitant use of zilucoplan with intravenous immunoglobulin or plasma exchange during RAISE and RAISE-XT
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Corticosteroid dose tapering in patients with generalized myasthenia gravis on zilucoplan: Interim analysis of RAISE-XT
Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
Oral Presentation American College of Rheumatology (ACR), 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Developing needs-driven medical education for healthcare professionals in myasthenia gravis
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Drivers of New Rozanolixizumab Treatment Cycles in Patients with Generalized Myasthenia Gravis in the Phase 3 MycarinG and Open-Label Extension Studies
Poster RheumNow Live! (RNL), 2024
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
Effect of rozanolixizumab on myasthenia gravis-specific outcome subdomain scores: Post hoc analyses from the Phase 3 MycarinG study
Efficacy of zilucoplan in patients with generalized myasthenia gravis without prior immunoglobulin or plasma exchange in the RAISE study
Evidence of misdiagnosis in administrative claims data for individuals with myasthenia gravis
Fragment Crystallizable (Fc)-Free Certolizumab Pegol is not Bound by Rheumatoid Factors, while Fc Containing Biological DMARDs Are, Driving Immune Complex Formation and Cellular Clearance
Medical Symposium American Academy of Neurology (AAN), 2024
Harnessing New Potential in Generalized Myasthenia Gravis (gMG): When Individuality Meets Optionality
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from the BE MOBILE 1 and 2 Phase 3 Studies
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Interactions of Fcy receptors with an IgG4 format, anti-FcRn monoclonal antibody, rozanolixizumab
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
Poster RheumNow Live! (RNL), 2024
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
Long-term safety and efficacy of zilucoplan in generalized myasthenia gravis: 120-week interim analysis of RAISE-XT
Long-Term Safety and Efficacy of Zilucoplan in Myasthenia Gravis: Additional Interim Analyses of RAISE-XT
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
Long-term safety outcomes of rozanolixizumab treatment in patients with generalized myasthenia gravis: A pooled analysis
Long-Term Sustained Efficacy and Safety of Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies
Long-term zilucoplan in generalized myasthenia gravis: 96-week follow-up interim analysis of RAISE-XT
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Oral Presentation American College of Rheumatology (ACR), 2024
Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis Over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
Minimal symptom expression in generalized myasthenia gravis: A post hoc analysis of MycarinG and open-label studies
Medical Symposium Muscular Dystrophy Association (MDA), 2024
Mitochondrial Myopathies Mimicking Neuromuscular Diseases: A Case-Based Exploration
Non-steroidal immunosuppressant therapy changes during treatment with zilucoplan in patients with generalized myasthenia gravis: 120-week follow-up of RAISE-XT
Oral Presentation American Academy of Dermatology (AAD), 2024
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
Oral Presentation International Congress on Neuromuscular Diseases (ICNMD), 2024
Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Patient experiences of thymidine kinase 2 deficiency (TK2d): preliminary results from an online survey conducted in partnership with the patient community
Patient Preferences for Myasthenia Gravis Treatments: A Discrete-Choice Experiment
Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Pharmacokinetics of Certolizumab Pegol in Pregnancy: Results from the Open-Label, Phase 1b CHERISH Study
Point-Counterpoint: An Expert-led Discussion on Generalized Myasthenia Gravis (gMG) Treatment Choice
Purified monoclonal rheumatoid factors bind to Fc containing TNF inhibitors in vitro but not to the Fc-free TNF inhibitor, certolizumab pegol
Rapid joint and skin responses were observed in patients with active psoriatic arthritis treated with bimekizumab: A pooled analysis from two phase 3 studies
Rapid, Sustained Improvements in Routine Assessment of Patient Index Data 3 in Bimekizumab-Treated Patients With Psoriatic Arthritis: Post-Hoc Analysis of Two Phase 3 Studies
Medical Symposium Neuromuscular Study Group (NMSG) Annual Scientific Meeting, 2024
Rare Disease Connect in Neurology (RDCN): An international MG community and forum providing needs-driven medical education
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
Reporting mental health and associated disorders from trials of bimekizumab in patients with active axial spondyloarthritis and psoriatic arthritis
Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Response rates with zilucoplan among generalized myasthenia gravis patients in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
Oral Presentation International Congress on Neuromuscular Diseases (ICNMD), 2024
Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT
Response to Rozanolixizumab Across Treatment Cycles in Patients with Generalized Myasthenia Gravis: A Post-hoc Analysis
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Rozanolixizumab in patients aged ≥65 years with generalized myasthenia gravis: A post hoc analysis of the Phase 3 MycarinG study
Rozanolixizumab treatment patterns in patients with generalized myasthenia gravis: Post hoc analysis
Oral Presentation International Congress on Neuromuscular Diseases (ICNMD), 2024
Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)
Safety, Efficacy, and Patient Preference for Subcutaneous Zilucoplan in Myasthenia Gravis After Switching from Intravenous Complement 5 Component 5 Inhibitors: An Interim Analysis of a Phase 3b Study
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Self-administration of subcutaneous rozanolixizumab in patients with generalized myasthenia gravis: Clinical study design
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Social determinants of health are associated with delayed diagnosis in myasthenia gravis
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Medical Symposium Immunoglobulin National Society (IgNS) National Conference, 2024
Subcutaneous Infusions in Generalized Myasthenia Gravis: Understanding the Administration of Rozanolixizumab-noli
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study
Switching to subcutaneous zilucoplan from IV complement component 5 inhibitors in myasthenia gravis: A Phase 3b study
The Safety and Efficacy of Chronic Weekly Rozanolixizumab Treatment in Patients with Generalized Myasthenia Gravis (MG0004)
Time to Diagnosis and Associated Comorbidity Burden in Axial Spondyloarthritis in General Practice in France: Results from the THIN® Database
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Utilizing Patient-Reported Data to Improve Understanding of Flare Predictors in Patients with Moderate to Severe Hidradenitis Suppurativa
Medical Symposium RheumNow Live! (RNL), 2024
Watch Video: Clinical Relevance of High Rheumatoid Factor in Patients with Rheumatoid Arthritis